Klaus Metzeler
Academic contribution (See all users)

By role

By subject area

Academic Editor

Klaus H Metzeler


Klaus Metzeler, MD, is a Senior Physician at the Department of Internal Medicine, Hematology and Oncology at the University of Munich, Germany.
He completed his clinical training at the University of Munich. During a research fellowship at The Ohio State Comprehensive Cancer Center (Columbus, OH, USA) under the mentorship of Clara D. Bloomfield and Guido Marcucci, he developed a strong interest in translational research, mainly focusing on leukemia genetics.
As a clinician-scientist, his current research interests are centered around understanding the genetic basis of myeloid neoplasms, and developing novel diagnostic tools, prognostic and predictive biomarkers, and ultimately more effective treatment approaches for patients with leukemia.
Dr. Metzeler has co-authored over 50 scientific publications.

Bioinformatics Clinical Trials Genetics Hematology Medical Genetics Oncology Translational Medicine

Work details

Senior Physician

Ludwig-Maximilians-Universität München
Hematology and Oncology
Since July 2016, I have been working as a senior physician in the laboratory for leukemia diagnostics. In addition to routine diagnostics in the field of molecular cytogenetics, I am especially interested in the development of innovative diagnostic procedures, in particular of "next generation sequencing", in the field of hematological research and diagnostics. My clinical focus is the care of patients with malignant diseases of the blood-forming system in the outpatient and inpatient area. I am particularly interested in the diagnosis and treatment of myeloid neoplasia (acute myelogenous leukemia, myelodysplastic syndromes and myeloproliferative neoplasia). I also provide clinical trials where new and innovative therapeutic concepts are made available to our patients. My scientific interest is the translational research in the field of myeloid neoplasia genetics. The starting point of my research was the investigation of the influence of certain genetic changes (mutations, gene expression profiles) on the prognosis of patients with acute myelogenous leukemia. Based on this, studies on the genetic heterogeneity and clonal evolution of myeloid neoplasia have recently been brought to the fore. Our working group "translational leukemia genetics" by the German Research Community in the SFB1243 special research area. Our long-term goal is to better understand how acute leukemias change in the course of the disease and under the influence of different therapies, and to derive more effective therapies.

PeerJ Contributions

Academic Editor on